Kadcyla is a combination of Herceptin and a chemo drug that work together to keep cancer cells from growing. It’s already approved by the US Food and Drug Administration to treat women with HER2 positive breast cancer
Is KADCYLA considered chemotherapy?
Kadcyla (ado-trastuzumab emtansine) is a new class of chemotherapy drug called an antibody-drug conjugate used to treat breast cancer.
How long can you stay on KADCYLA?
For HER2+ early breast cancer, KADCYLA is given every 3 weeks for 14 rounds of infusion—sometimes called “cycles”—unless the cancer comes back or side effects cause the treatment to be stopped sooner. Treatment with KADCYLA typically would last less than a year.
Is KADCYLA chemotherapy or immunotherapy?
Kadcyla is a combination of Herceptin and the chemotherapy medicine emtansine. Doctors call Kadcyla an antibody-drug conjugate targeted therapy.What type of drug is KADCYLA?
KADCYLA is the first HER2-targeted treatment of its kind. It is made up of two cancer-fighting agents in one drug: The monoclonal antibody trastuzumab (the same antibody in Herceptin®) A chemotherapy.
How good is Kadcyla?
Overall, 71.4% of people treated with Kadcyla and 81.0% of people treated with Herceptin completed all 14 cycles of treatment. Of the 133 people who stopped Kadcyla treatment early, 71 switched to Herceptin, and 63 of those people completed 14 cycles of anti-HER2 therapy.
Do you lose your hair with Kadcyla?
Hair loss usually starts after your first or second treatment. It is almost always temporary, and your hair will usually grow back after treatment finishes.
Can I drink alcohol with Kadcyla?
You may feel tired or dizzy after your treatment. What NOT to DO while on this medication: DO NOT smoke or drink alcohol while on treatment without talking to your health care team first. Smoking and drinking can make side effects worse and make your treatment not work as well.How long does Kadcyla infusion take?
Kadcyla is given to you as an intravenous (IV) infusion into your vein. You will receive this medicine in your doctor’s office, at a hospital, or at an infusion center. Your first infusion will last about 90 minutes. After that, each infusion should take about 30 minutes if you tolerate your first infusion well.
Can Kadcyla cause neuropathy?Adverse Reactions. The most common adverse reactions seen with KADCYLA in the KATHERINE trial (frequency >25%) were fatigue, nausea, increased transaminases, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, peripheral neuropathy, and arthralgia.
Article first time published onWhy is Kadcyla given?
Kadcyla Indication Statements Patients are selected for therapy based on an FDA-approved test for Kadcyla. Kadcyla is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin) and a taxane.
How long do you take Phesgo?
PHESGO is given every 3 weeks until the cancer progresses or side effects become too difficult to manage.
How often is Kadcyla given?
The recommended dose of KADCYLA is 3.6 mg/kg given as an intravenous infusion 26 every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
Does Phesgo cause hair loss?
The most common side effects of PHESGO when given with chemotherapy as part of an early breast cancer regimen are hair loss, nausea, diarrhea, low levels of red blood cells, and weakness.
How much does Phesgo cost?
QuantityPer unitPrice15 milliliters$885.04$13,275.61
Does Phesgo cause neuropathy?
nausea. fatigue. rash. peripheral neuropathy (numbness, tingling, or pain in the hands and feet)
How do you administer Kadcyla?
- Administer KADCYLA as an intravenous infusion only with a 0.2 or 0.22 micron in-line polyethersulfone (PES) filter. Do not administer as an intravenous push or bolus.
- Do not mix KADCYLA, or administer as an infusion, with other medicinal products.
What class of drug is Phesgo?
This medication is classified as an antineoplastic agent and anti-HER2 monoclonal antibody (For more detail, see “How Pertuzumab, trastuzumab, and hyaluronidase Works” below).
Is pertuzumab a chemotherapy?
Pertuzumab is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. This medication is classified as an “antineoplastic agent and a monoclonal antibody”. (For more detail, see “How Pertuzumab Works” below).
How does Phesgo work?
When PHESGO is injected, the hyaluronidase makes the tissue under the skin more absorbent temporarily so that it’s able to receive the medication. Once it’s absorbed by your body, the PERJETA and Herceptin inside PHESGO are thought to work the same way to treat your HER2+ breast cancer.
